Stocks in play: Microbix Biosystems Inc.
Announced that it is presenting results of Quality Assessment Products for supporting the quality control of histology and PCR-based tests driven by tissue-samples of Head and Neck cancer caused by human papilloma virus. Its results presentation will be made at EUROGIN 2024, an international collaborative conference and exhibition focused upon innovations in HPV research and global cancer solutions taking place in Stockholm, Sweden from March 13 to 16. Microbix Biosystems Inc. shares T.MBX are trading unchanged at $0.39.
Read:
Global Efforts Intensify to Address Surging Young Adult Colorectal and Anal Cancer Rates
Harnessing AI's $4.4 Trillion Potential Reshapes the Tech Industry Landscape
Critical Push for US Domestic Nickel Needed to Halt Total Reliance on Questionable Foreign Imports
How Argentina’s New Power Moves Look to Lure Even More Lithium Interest Towards the Country
How Recent Biotech Breakthroughs Are Changing the Fight Against Breast Cancer